Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer

Journal of Palliative Medicine

Volumn 10, Issue 1, 2007, Pages 61-66

  Gordinier, Mary E ^a,c   Dizon, Don S ^b   Weitzen, Sherry ^b   Disilvestro, Paul A ^b   Moore, Richard G ^b   Granai, C O ^b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; IMMUNOMODULATING AGENT; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FUNCTIONAL ASSESSMENT; HEMATOLOGIC DISEASE; HUMAN; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OGILVIE SYNDROME; OVARY CANCER; PERITONEUM CANCER; PLEURA EFFUSION; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT CANCER; SEDATION; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PALLIATIVE CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; THALIDOMIDE;

EID: 33846929174     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.0083     Document Type: Article

References (19)

1. Donovan KA, Greene PC, Sinister JL, Partridge EE, Tucker DC: Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002;86:200-211.
2. th ed. Philadelphia: Lippincott Williams & Wilkins, 2005, pp. 895-987.
3. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-4085.
4. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Opthalmol 1998;236:461-466.
5. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB: Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;21:2299-2304.
6. Fujii T, Tachibana M, Dhar DK, Ueda S, Kinugasa S, Yoshimura H, Kohno H, Nagasue N: Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res 2003;23:2405-2411.
7. Macpherson CR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK, Figg WD: Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit Rev Oncol Hematol 2003;46(suppl):S49-57.
8. Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822-827.
9. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SRD, Ahern R, Smith IE, Gore ME: Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:81.2-817.
10. Eisen TG: Thalidomide in solid tumors: the London experience. Oncology 2000;14:17-20.
11. Abramson N, Stokes PK, Luke M, Marks AR, Harris JM: Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide. J Clin Oncol 2002;20:1147-11149.
12. Ciaravino G, Vela AM, Roberts J A, Teng NH: Thalidomide treatment of ovarian carcinoma - A preliminary analysis. Western Association of Gynecological Oncologists, 2000.
13. Ciaravino G, Vela AM, Roberts SC, Teng NH: Preliminary analysis of thalidomide in gynecologic malignancies [Abstract 153]. Society of Gynecologic Oncologists, 2001.
14. Ciaravino G, Husain A, Vela AM, Roberts JA, Teng NH: A study of tolerance and outcome of thalidomide in patients with epithelial ovarian and peritoneal carcinomas [Abstract 1859]. American Society of Clinical Oncologists, 2003.
15. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Lloyd S, Purl S, Blendowski C, Goodman M, Barnicle M, Stewart I, McHale M, Bonomi P, Kaplan E, Taylor S, Thomas CR, Harris J: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993;11:570-579.
16. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM: Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001;19:1809-1817.
17. RECIST Working Group: Response evaluation criteria in solid tumors (RECIST Criteria). Natl Cancer Inst 1999;1-26.
18. Bridgewater JA, Nelstrop AE, G Rustin, ME Gore, WP McGuire, WJ Hoskins: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17:501-508.
19. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Rand t M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.